FIGURE 1.

Effect of marstacimab and/or rFVIIa on thrombin generation in nonhemophilic plasma and severe hemophilia A and B human plasma with inhibitors. Thrombin generation was measured in the presence of 1 pM TF and 4 µM phospholipids. Shown are the thrombograms from each donor hemophilia A plasma with an inhibitor (3, 102, and 1261 BU) and hemophilia B with an inhibitor (14 BU). The following were added to each individual hemophilia A plasmas: vehicle (50% PBS/50%HEPES); rFVIIa (2 μg/ml), marstacimab alone (16 μg/ml); and marstacimab (16 μg/ml) in combination with rFVIIa (2 μg/ml). Thrombin generation was also measured in nonhemophilic plasma alone and with marstacimab (16 μg/ml). Abbreviations: BU, Bethesda unit; HEPES, 4‐(2‐hydroxyethyl)‐1‐piperazineethanesulfonic acid; PBS, phosphate buffered saline; rFVIIa, recombinant factor VIIa; TF, tissue factor